CUE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.75M

+11.04%

-0.100

-21.87%

2.50M

+493.82%

-0.110

-35.29%

2.50M

-15.37%

-0.120

+33.33%

Estimates Revision

The market is revising Upward the revenue expectations for Cue Biopharma, Inc. (CUE) for FY2025, with the revenue forecasts being adjusted by 11.54% over the past three months. During the same period, the stock price has changed by -37.75%.

Revenue Estimates for FY2025

Revise Upward

+11.54%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-37.75%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Cue Biopharma Inc (CUE.O) is -1.02, compared to its 5-year average forward P/E of -3.57. For a more detailed relative valuation and DCF analysis to assess Cue Biopharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.57

Current PE

-1.02

Overvalued PE

-1.04

Undervalued PE

-6.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.60

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.01

Undervalued EV/EBITDA

-4.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

44.29

Current PS

0.00

Overvalued PS

101.46

Undervalued PS

-12.89

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CUE News & Events

Events Timeline

No data

News

2.0

12-11NASDAQ.COM

Biotech Stocks Rise in After-Hours Trading Driven by Data Expectations and Momentum Buying

4.0

12-06NASDAQ.COM

Cue Biopharma (CUE) Price Target Raised by 25% to $5.10

2.0

12-05NASDAQ.COM

Healthcare and Biotech Stocks Surge in After-Hours Trading: Sensei, Praxis, Cooper, Vanda, Cue, ResMed

People Also Watch

Frequently Asked Questions

What is Cue Biopharma Inc (CUE) stock price today?

The current price of CUE is 0.4625 USD — it has decreased -5.13 % in the last trading day.

What is Cue Biopharma Inc (CUE)'s business?

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.

What is the price predicton of CUE Stock?

Wall Street analysts forecast CUE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CUE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cue Biopharma Inc (CUE)'s revenue for the last quarter?

Cue Biopharma Inc revenue for the last quarter amounts to 2.15M USD, decreased -35.58 % YoY.

What is Cue Biopharma Inc (CUE)'s earnings per share (EPS) for the last quarter?

Cue Biopharma Inc. EPS for the last quarter amounts to -0.07 USD, decreased -58.82 % YoY.

What changes have occurred in the market's expectations for Cue Biopharma Inc (CUE)'s fundamentals?

How many employees does Cue Biopharma Inc (CUE). have?

Cue Biopharma Inc (CUE) has 41 emplpoyees as of December 16 2025.

What is Cue Biopharma Inc (CUE) market cap?

Today CUE has the market capitalization of 36.42M USD.